June 7, 2017 / 11:19 AM / 5 months ago

BRIEF-Calithera says FDA fast track designation granted to CB-839

June 7 (Reuters) - Calithera Biosciences Inc:

* Calithera Biosciences announces FDA fast track designation granted to CB-839 for treatment of patients with renal cell carcinoma

* Calithera Biosciences - “look forward to initiating a global randomized trial of CB-839 in combination with everolimus for treatment of renal cell carcinoma in second half of 2017” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below